Histology-Tailored Approach to Soft Tissue Sarcoma

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Aug 22

PMID 39174839

Authors

Mai-Kim Gervais

Georges Basile

Jean-Philippe Dulude

Sophie Mottard

Alessandro Gronchi

Affiliations

Soon will be listed here.

Abstract

Soft tissue sarcomas are a diverse and heterogeneous group of cancers of mesenchymal origin. Each histological type of soft tissue sarcoma has unique clinical particularities, which makes them challenging to diagnose and treat. Multidisciplinary management of these rare diseases is thus key for improved survival. The role of surgery has been well established, and it represents the cornerstone curative treatment for soft tissue sarcomas. To date, local recurrence is the leading cause of death in low-grade sarcomas located at critical sites, and distant metastasis in high-grade sarcomas, regardless of the site of origin. Management must be tailored to each individual histologic type. We describe the most common types of extremity, trunk, abdominal, and retroperitoneal soft tissue sarcoma along with characteristics to consider for optimized management.

Citing Articles

From Data Integration to Precision Medicine: A Value-Based Healthcare Approach for Sarcoma Care.

Fuchs B, Heesen P J Clin Med. 2024; 13(21).

PMID: 39518639 PMC: 11546467. DOI: 10.3390/jcm13216500.

What Is the Prognostic Value of the Pathologic Response after Neoadjuvant Radiotherapy in Soft Tissue Sarcoma? An Institutional Study Using the EORTC-STBSG Response Score.

Stergioula A, Kormas T, Kokkali S, Memos N, Pantelis E, Pouloudi D Cancers (Basel). 2024; 16(20).

PMID: 39456543 PMC: 11506461. DOI: 10.3390/cancers16203449.

References

Gatta G, van der Zwan J, Casali P, Siesling S, Dei Tos A, Kunkler I . Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011; 47(17):2493-511. DOI: 10.1016/j.ejca.2011.08.008. View

Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss D, Levy A . Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016; 17(5):671-80. DOI: 10.1016/S1470-2045(16)00010-3. View

Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B . The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019; 109:51-60. DOI: 10.1016/j.ejca.2018.12.009. View

Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G . Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2021; 128(1):85-93. DOI: 10.1002/cncr.33895. View

Lambdin J, Ryan C, Gregory S, Cardona K, Hernandez J, van Houdt W . A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2). Ann Surg Oncol. 2023; 30(8):4573-4575. PMC: 10687743. DOI: 10.1245/s10434-023-13500-9. View

Gronchi A, Colombo C, Raut C . Surgical management of localized soft tissue tumors. Cancer. 2014; 120(17):2638-48. DOI: 10.1002/cncr.28715. View

Weiss S . Lipomatous tumors. Monogr Pathol. 1996; 38:207-39. View

Nishio J, Nakayama S, Chijiiwa Y, Aoki M . Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities. Anticancer Res. 2023; 43(10):4295-4301. DOI: 10.21873/anticanres.16624. View

Choi K, Jost E, Mack L, Bouchard-Fortier A . Surgical management of truncal and extremities atypical lipomatous tumors/well-differentiated liposarcoma: A systematic review of the literature. Am J Surg. 2020; 219(5):823-827. DOI: 10.1016/j.amjsurg.2020.01.046. View

10.

Rauh J, Klein A, Baur-Melnyk A, Knosel T, Lindner L, Roeder F . The role of surgical margins in atypical Lipomatous Tumours of the extremities. BMC Musculoskelet Disord. 2018; 19(1):152. PMC: 5960141. DOI: 10.1186/s12891-018-2053-3. View

11.

Kito M, Yoshimura Y, Isobe K, Aoki K, Momose T, Suzuki S . Clinical outcome of deep-seated atypical lipomatous tumor of the extremities with median-term follow-up study. Eur J Surg Oncol. 2014; 41(3):400-6. DOI: 10.1016/j.ejso.2014.11.044. View

12.

Vos M, Grunhagen D, Kosela-Paterczyk H, Rutkowski P, Sleijfer S, Verhoef C . Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. Surg Oncol. 2019; 29:84-89. DOI: 10.1016/j.suronc.2019.04.004. View

13.

Kido A, Kitagawa Y, Tsukushi S, Iwata S, Ishida Y, Tsukamoto S . Marginal resection for patients with atypical lipomatous tumours of the extremities and trunk wall: a systematic review and meta-analysis. Jpn J Clin Oncol. 2021; 52(2):151-156. DOI: 10.1093/jjco/hyab185. View

14.

Tfayli Y, Baydoun A, Naja A, Saghieh S . Management of myxoid liposarcoma of the extremity. Oncol Lett. 2021; 22(2):596. PMC: 8228380. DOI: 10.3892/ol.2021.12857. View

15.

Chowdhry V, Goldberg S, DeLaney T, Cote G, Chebib I, Kim J . Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy. Sarcoma. 2018; 2018:8029157. PMC: 6236966. DOI: 10.1155/2018/8029157. View

16.

Durr H, Rauh J, Baur-Melnyk A, Knosel T, Lindner L, Roeder F . Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. BMC Cancer. 2018; 18(1):304. PMC: 5859402. DOI: 10.1186/s12885-018-4226-8. View

17.

Muratori F, Greto D, Cenatiempo M, Mazzei G, Frenos F, Roselli G . Leiomyosarcoma: Clinicopathological study and retrospective analysis of prognostic factors in a series of 100 patients. J Orthop. 2019; 16(4):303-307. PMC: 6441716. DOI: 10.1016/j.jor.2019.03.004. View

18.

Yu J . Myxoid liposarcoma: a well-defined clinical target variant in radiotherapy for soft tissue sarcoma. Radiat Oncol J. 2023; 40(4):213-215. PMC: 9830037. DOI: 10.3857/roj.2022.00598. View

19.

Muratori F, Bettini L, Frenos F, Mondanelli N, Greto D, Livi L . Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution. Int J Surg Oncol. 2018; 2018:8928706. PMC: 6011058. DOI: 10.1155/2018/8928706. View

20.

Visgauss J, Wilson D, Perrin D, Colglazier R, French R, Mattei J . Staging and Surveillance of Myxoid Liposarcoma: Follow-up Assessment and the Metastatic Pattern of 169 Patients Suggests Inadequacy of Current Practice Standards. Ann Surg Oncol. 2021; 28(12):7903-7911. DOI: 10.1245/s10434-021-10091-1. View